{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:42Z","timestamp":1793230662658,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ard.2026.07.016","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:19:19Z","timestamp":1788434359000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune reset after deep B-lineage depletion: remission is not reprogramming"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-5895","authenticated-orcid":false,"given":"Marc","family":"Scherlinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ard.2026.07.016_bib0001","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2026.07.016_bib0002","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41573-025-01242-0","article-title":"Advances in the treatment of systemic lupus erythematosus","volume":"24","author":"Scherlinger","year":"2025","journal-title":"Nat Rev Drug Discov."},{"issue":"6","key":"10.1016\/j.ard.2026.07.016_bib0003","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.07.016_bib0004","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.ard.2026.07.016_bib0005","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat Rev Immunol."},{"issue":"6","key":"10.1016\/j.ard.2026.07.016_bib0006","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/s41591-026-04430-6","article-title":"Resetting autoimmune disease with CAR cell therapies","volume":"32","author":"Schett","year":"2026","journal-title":"Nat Med."},{"issue":"8","key":"10.1016\/j.ard.2026.07.016_bib0007","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","article-title":"The immunology of systemic lupus erythematosus","volume":"25","author":"Tsokos","year":"2024","journal-title":"Nat Immunol."},{"issue":"12","key":"10.1016\/j.ard.2026.07.016_bib0008","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.07.016_bib0009","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41467-024-45080-x","article-title":"CaMK4 controls follicular helper T cell expansion and function during normal and autoimmune T-dependent B cell responses","volume":"15","author":"Scherlinger","year":"2024","journal-title":"Nat Commun."},{"issue":"4","key":"10.1016\/j.ard.2026.07.016_bib0010","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jaci.2018.12.996","article-title":"A new checkpoint in lupus","volume":"143","author":"Tsokos","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.ard.2026.07.016_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0065-2776(08)60342-9","article-title":"Murine models of systemic lupus erythematosus","volume":"37","author":"Theofilopoulos","year":"1985","journal-title":"Adv Immunol."},{"issue":"11","key":"10.1016\/j.ard.2026.07.016_bib0012","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-025-03987-y","article-title":"Developing cell therapies for lupus","volume":"31","author":"Merrill","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ard.2026.07.016_bib0013","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med."},{"issue":"2","key":"10.1016\/j.ard.2026.07.016_bib0014","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.07.016_bib0015","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med."},{"issue":"6","key":"10.1016\/j.ard.2026.07.016_bib0016","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ard.2026.02.002","article-title":"Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series","volume":"85","author":"Scherlinger","year":"2026","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.07.016_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-026-04238-4","article-title":"Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases","volume":"32","author":"D\u00fcsing","year":"2026","journal-title":"Nat Med."},{"issue":"9","key":"10.1016\/j.ard.2026.07.016_bib0018","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ard.2026.07.016_bib0019","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell\u2013engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.ard.2026.07.016_bib0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.ard.2026.07.016_bib0021","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jid.2021.05.038","article-title":"B- and plasma cell subsets in autoimmune diseases: translational perspectives","volume":"142","author":"Dang","year":"2022","journal-title":"J Invest Dermatol."},{"issue":"6","key":"10.1016\/j.ard.2026.07.016_bib0022","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ard.2026.07.016_bib0023","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.07.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.05.023","article-title":"Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis\u2014a case series","author":"Siegert","year":"2026","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.07.016_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2026.05.021","article-title":"Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series","author":"Albach","year":"2026","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.ard.2026.07.016_bib0026","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med."},{"issue":"16","key":"10.1016\/j.ard.2026.07.016_bib0027","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell."},{"issue":"9","key":"10.1016\/j.ard.2026.07.016_bib0029","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.ard.2026.07.016_bib0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ard.2026.07.016_bib0031","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fimmu.2019.00782","article-title":"B Cell reconstitution and influencing factors after hematopoietic stem cell transplantation in children","volume":"10","author":"van der Maas","year":"2019","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.ard.2026.07.016_bib0032","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2015-06-649145","article-title":"Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells","volume":"127","author":"Delemarre","year":"2016","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.ard.2026.07.016_bib0033","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2005-07-2800","article-title":"Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network","volume":"107","author":"de Kleer","year":"2006","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.ard.2026.07.016_bib0034","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight."},{"issue":"3","key":"10.1016\/j.ard.2026.07.016_bib0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/ard-2021-221925","article-title":"Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more na\u00efve state in patients with systemic sclerosis","volume":"82","author":"Adamska","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.07.016_bib0036","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:19:24Z","timestamp":1788434364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726004735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S0003496726004735"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.07.016","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune reset after deep B-lineage depletion: remission is not reprogramming","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}